young child near Hyundai Hope on Wheels vehicle with painted handprints

Grant Support

Current Grant Support

Hyundai Hope on Wheels, “Targeted radiotherapy with alkyl phosphocholine analogs for refractory childhood leukemia” (2019-2021). Otto, PI

Hyundai Hope on Wheels, “Effects of molecular targeted radionuclide therapy on the immune microenvironment in medulloblastoma” (2019-2021). Otto, Mentor for N. Pytel

AACR-St. Baldrick’s, “Immunogenomics to create new therapeutics for high risk childhood cancers” (2017-2021). Otto, Young Investigator

UW ICTR, “Development of pre-clinical models and clinical applications for T cell receptor alpha beta depleted haploidentical stem cell transplant” (2018-2020). Otto, Mentor for S. Rinella

Cannonball Kids’ Cancer Foundation, “TCR-alpha/beta+ and CD19+ depleted KIR/KIR ligand-mismatched haploidentical hematopoietic stem cell transplant and Zoledronate for pediatric relapsed/refractory hematologic malignancies and high risk solid tumors” (2016-2020). Otto, PI

Cellectar Biosciences, Inc., “A phase 1, open-label, dose escalation study of CLR 131 in children and adolescents with select solid tumors, lymphoma, and malignant brain tumors” (2018-ongoing). Otto, site PI

MACC Fund, “Targeted molecular radiotherapy to improve the outcomes in children with malignant brain tumors” (2017-2019). Otto, PI

MACC Fund, “Strategies for improving recovery of immune function following TCRab-depleted hematopoietic stem cell transplantation” (2017-2019). Otto, PI

UW Office of the Vice Chancellor for Research and Graduate Education and the UW Carbone Cancer Center, “Combining radiotherapeutic with antitumor antibody and IL2 to create a potent in situ cancer vaccine” (2016-2019). Otto, Co-PI


Completed Grant Support

St. Baldrick’s, “Improving anti-cancer immune responses to targeted radionuclide therapy” (2018-2019). Otto, PI

NIH/NCI & University of Wisconsin Carbone Cancer Center (P30 CA014520), “TCR-α/β+ and CD19+ depleted KIR/KIR ligand-mismatched haploidentical hematopoietic stem cell transplant and Zoledronate for pediatric relapsed/refractory hematologic malignancies and high risk solid tumors” (2016-2018). Otto, Pilot Grant PI

Hyundai Hope on Wheels, “A novel phospholipid ether analog to combine targeted molecular radiotherapy and immunotherapy in pediatric solid tumors” (2015-2018). Otto, PI

American Association of Immunologists (K. Kloepping fellowship), “A novel phospholipid ether analog to combine targeted molecular radiotherapy and immunotherapy in pediatric solid tumors,” (2016-2017). Otto, Mentor

Midwest Athletes Against Childhood Cancer, “Effect of Zoledronate on engraftment and t-cell development after TCR alpha-ß/CD19-depleted hematopoietic stem cell transplantation” (2015-2017). Otto, PI

NIH/NCI (R21 CA198392), “A cancer-targeted phospholipid ether analog for molecular radiotherapy of pediatric solid tumors” (2015-2017). Otto, PI

Midwest Athletes Against Childhood Cancer, “Clr1404 – A tumor-selective alkyl phospholipid analog for the treatment of pediatric solid malignancies” (2015-2017). Otto, PI

AACR-St. Baldrick’s-SU2C Foundations “Immunogenomics to create new therapies for high-risk childhood cancers” (2013-2017). Otto, Young Investigator

Midwest Athletes Against Childhood Cancer, “Alpha/beta t-cell depleted haploidentical transplantation with post-transplant zoledronic acid to treat recurrent or refractory pediatric malignancies” (2013-2016). Otto, Co-Investigator

Midwest Athletes Against Childhood Cancer, “Development of multifunctional superparamagnetic anti-GD2 nanoparticles for simultaneous molecular imaging, cancer cell targeting and drug delivery” (2011-2015). Otto, PI

Alex’s Lemonade Stand Foundation for Childhood Cancer, “Development of an innovative treatment strategy for neuroblastoma and other pediatric tumors: a novel phospholipid ether analogue and its multifunctional cancer-targeting nanoconstruct” (2012-2014). Otto, PI